phenyl]-2-methylacrylate) is a known inhibitor of throm boxane synthesis, a class of agents thought potentially useful in treating conditions characterized by platelet aggregation. Doses of 10, 100, and 300 mg/kg were ad ministered intraperitoneally to mice 1 h before their pial vessels were injured by a combination of light from a filtered mercury lamp and intravascular sodium fluores cein. In this model platelet aggregation and arterial dila tion are produced. Pretreatment with OKY-1581 had no effect except at the 300-mg/kg dose, which enhanced aggregation as manifested by a decrease in the time required for the noxious stimulus to initiate aggrega-
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tion. In addition the dilation increased in magnitude as compared with that in controls. The latter result is com patible with a decreased synthesis of thromboxane, a known constrictor of cerebral vessels. However, the en hancement of aggregation by a high dose of OKY-1581 was unexpected and paradoxical. The data do not support the use of thromboxane synthesis inhibitors as therapy for conditions caused by platelet aggregation, but the results may be dependent upon the species, the vascular bed, or the method used to induce aggregation. Key Words: Ce rebral microcirculation-Platelet aggregation-Throm boxane synthesis inhibitor-Vascular injury-Vasodila tion.
platelet aggregation within injured cerebral vessels. This expectation arose from the knowledge that thromboxane is synthesized during platelet aggre gation and that it, as well as some of its metabolic precursors, has been implicated as a mediator of aggregation (Smith, 1980) . Instead of observing an inhibition of aggregation, we found that aggregation was enhanced, as shown by a decrease in the time required for a noxious stimulus to initiate aggrega tion.
The stimulus used in this study was previously employed by us to demonstrate that known inhib itors of aggregation acted in the expected manner in the in vivo model (Rosenblum and EI-Sabban, 1977, 1979) . We also used this stimulus in studies showing that tranylcypromine, an inhibitor of prostacyelin synthesis, enhanced aggregation (Rosenblum and El-Sabban, 1978) , a result expected because prosta cyelin is a potent in vitro inhibitor of aggregation (Smith, 1980) and because local application of prostacyelin inhibited aggregation in our model (Rosenblum and EI-Sabban, 1979) and in a quite different in vivo model of aggregation (Higgs et al. , 1977) . Because of our prior data, we feel secure in our belief that the present model is a valid one for testing drugs of known action on the throm boxane-prostacyclin synthetic pathways, with the intention of establishing the extent to which ma nipulation of these pathways can actually alter platelet aggregation in a pathologic setting.
METHODS
Our model and methods are described in great detail in earlier publications (Rosenblum and EI-Sabban, 1977 , 1978 Rosenblum, 1978) . Briefly, male mice (In ternational Cancer Research strain, Flow Laboratories) were anesthetized with urethane. Microvascular injury and platelet aggregation were produced by exposing the microscopic field to light from a filtered mercury lamp (200 W) in the presence of intravascular sodium fluores cein (0.2 ml of 2% solution/25 g body weight, given via tail vein). The filters were a Leitz KG-l and a Leitz dichroic reflecting filter, which virtually exclude wavelengths above 800 or below 350 'A. In addition a Leitz BG-12 ex citer filter was used and the fluorescein excited at 475 'A. It should be stressed that because of the filters, ultraviolet light is not responsible for the damage we produced. Neither the light alone nor the dye alone induces aggrega tion, and aggregates are not found outside the illuminated microscopic field. Moreover, illumination of a platelet rich suspension containing fluorescein and placed at the focal plane of the microscope failed to induce aggrega tion. Therefore we believe aggregation is induced by en dothelial injury. We demonstrated such injury with the electron microscope (Rosenblum and EI-Sabban, 1977; Povlishock et aI., 1982) in the absence of injury to red cells or platelets. Originally we suggested that the injury was produced by heat, but recent data suggest it is pro duced by free radicals generated when the light excites the dye (Rosenblum and EI-Sabban, 1982a) .
By measuring the time from onset of the exposure to the appearance of the initial aggregate adhering to the wall of a preselected vessel, we assessed the degree of aggre gation in vivo. Recognition of the adhering aggregate was facilitated by the fact that aggregates fluoresce in this system. A control mouse was examined immediately after or before each mouse that had received OKY-1581, the sequence being randomized. This alternation of control and drug-treated animals was adopted in our initial publi cation with the light/dye technique (Rosenblum and EI Sabban, 1977) , and is essential to avoid the confusing effects produced by variability in the responses of animals examined at different periods of time (Rosenblum and EI-Sabban, 1978) .
Internal diameters of the vessels in this study were measured with an ocular micrometer and, for the ar terioles, ranged from 25 to 55 JLm with a mean of ap proximately 40 JLm (e.g., 39 ± 5 JLm in one study, 33 ± 3 JLm in another, mean ± SD). No significant differences in baseline diameter were found between groups of vehicle-treated and drug-treated mice, so these basal val ues will not be referred to again. When injured by the light/fluorescein, the arterioles dilated (Rosenblum et aI., 1980) and the diameter prior to the onset of the noxious stimulus could be compared with that following the com plete occlusion of the arteriole by a platelet aggregate(s). This occurred within 5 min. The diameter was expressed as a percentage of the original diameter. Thus, if a vessel 40 JLm in size dilated to 50 JLm, it had a diameter 125% that of the original.
Mice were injected intraperitoneally, immediately after craniotomy, with either OKY-1581 or its saline vehicle.
Exposure to the noxious lightlfluorescein occ � rr�d 1 � later. Prior to this all observations were made With illumi nation from a tungsten source except for a period of about 3 min when the mercury lamp with a green filter was employed during the measurement of red cell velocity.
The red blood cell velocity Johnson, 1967' Baker and Wayland, 1974) was measured in each arte;iole just prior to the onset of the noxious light! fluorescein. From the velocity and diameter, the shear rate at the wall was calculated (Barbee and Cokelet, 1971; Lipowsky et aI., 1978) . This was done because of a direct relationship between the magnitude of the shear rate and the length of time required to induce aggregation (Rosenblum and EI-Sabban, 1982h ). If the OKY-1581 were to produce a significant drop in shear rat � , for example by causing blood pressure and flow velOCity to fall then the onset of aggregation might be shortened not bec ' ause of an effect on platelet thromboxane synthesis, but because of the fall in shear rate. The measurements of red blood cell velocity were made with the two-slit photometric technique (Tomkins et aI., 1974; Lipowsky et aI., 1978; Rosenblum and EI-Sabban, 1981; Rosenblum and EI-Sabban, 1982h) .
Arterial pH, O2, and CO2 were measured at the end of each experiment. OKY-1581 failed to influence these val ues and they will not be mentioned further.
Because we observed no inhibitory effect on aggrega tion we felt it important to demonstrate that OKY-1581 did inhibit thromboxane production in mouse platelets. A simple bioassay was used as first described by Hamberg et al. (1974) . Platelet-rich plasma (PRP) (250 JLI) was used as the test object. It was stimulated with 0.5 mM arachidonate (sodium salt, 99% pure Nuchek, U.S.A.). Aggregation was monitored as a change in light transmis sion in an aggregometer (Chronolog, U.S.A.) at 37°C. At 90 s 50 JLI was transferred to a cuvette in a second ag gregometer which contained 250 JLI of PRP that h�d be � n prepared from blood of mice injected i. p . 1 h earlier �� th 100 mg aspirin per kilogram body weight. The aspmn treated PRP did not react to arachidonic acid, signifying that its cyclooxygenase was inhibited. l!nder thes . e . cir cumstances, any aggregation produced III the recIpient PRP by the 50 JLI of donor PRP could be ascribed not to residual arachidonate transferred from the latter, but rather to thromboxane A2 produced by the aggregating donor platelets. This aggregating material was extremely labile at room temperature, disappearing in 5 min, as does thromboxane A2. Moreover, its appearance was markedly inhibited by incubating the donor PRP with imidazole, 500 JLg/ml, for 10 min at 23°C, prior to stimulating the pl � tel � ts with arachidonic acid. Since imidazole is a known Illhlb itor of thromboxane synthesis (Moncada et aI., 1977) , these data further support the assumption that the labile proaggregatory material liberated by arachidonate stimulated platelets is, in fact, thromboxane.
RESULTS
Initially we performed two studies using 300 mg/kg, each study with a different lot of OKY-1581 (Table 1 ). In the first study the dilation produced by Two experiments are shown. Both show that OKY-158 1 significantly shortens the time required for the noxious stimulus to induce aggregation (analysis of covariance with shear rate as the covariant). This was true in spite of the shorter control values in experiment 2 compared with experiment 1. In both studies the diameter of the arterioles increased after injury and in both this increase was aug mented in the drug-treated mice. This augmenting effect of the drug was significant in experiment 1 (Student's t test). the lightlfluorescein was enhanced by drug treat ment and the aggregation was speeded up. The sec ond study showed similar results, but there only the effect of the drug on aggregation was statistically significant. In both studies shear rate was moni tored in the arterioles just prior to initiating aggre gation and was found to be lower in the drug-treated mice (1,129 ± 258 S-1 vs. 1,475 ± 153 S-1 in the first study and 1,034 ± 396 S-1 vs. 1, 331 ± 278 S-1 in the second). When the direct relationship between the magnitude of the shear rate and the time required to initiate aggregation was taken into account by use of analysis of covariance, the drug effect on aggrega tion remained significant (p < 0.02).
A third study, using 100 mg/kg OKY, was inef fective. In order to verify this result and to examine the drug's effect over an even wider dose range, a fourth study was done, the data from which are summarized in Table 2 . The OKY was from the same lot as that of the second study in Table 1 , but now the enhancing effect of the drug on dilation was statistically significant. The enhancing effect of the drug on aggregation remained significant, as it had been in the first and second studies. In confirmation of the preliminary study with 100 mg/kg, this dose was not effective, nor was 10 mg/kg.
In order to check on the ability of OKY-1581 to inhibit thromboxane production by mouse platelets, we assayed production of a thromboxane-like mate rial released from arachidonate-stimulated donor platelets, as described in Methods. Dose-dependent inhibition of thromboxane production was achieved with 250, 300, and 500 �g/ml of OKY-1581, pro ducing an 18 ± 10, 24 ± 8, and 74 ± 44% reduction (p < 0.01) in the aggregation produced by 50 �l of donor PRP transferred to recipient PRP.
DISCUSSION
OKY-1581 is a selective inhibitor of thromboxane synthesis (Feuerstein and Ramwell, 1981) . Since thromboxane generation from prostaglandin en doperoxides may be one mechanism responsible for platelet aggregation (Hamberg et aI., 1975; Smith, 1980) , it has been thought that OKY-1581 would retard aggregation in vivo. In data provided by the ONO Pharmaceutical Co. (Osaka, Japan), which supplied OKY, such retardation was reported in vitro a Study performed with 10 control mice and 10 mice at each dose level ofOKY-1581. b Analysis of variance showed a significant effect of the drug (p < 0.05), due par ticularly to the effect of the highest dose (Bonferroni test; Wallenstein et aI., 1980) . The drug effect was observed both as an enhancement of platelet aggregation, mani fested by the shortened latency, and also as enhancement of the arteriolar dilation that accompanied injury.
for rabbit platelets when 10-7 M drug was used and exogenous arachidonate was the aggregating stimulus. However, much higher (10-4 M) concen trations were required to inhibit the aggregation in duced in rat or guinea pig platelets by collagen. These high concentrations resemble those used in the present study. ONO also reports that doses up to 10-3 M had no effect on production of PG E2 or of 6-keto-PGFla by peritoneal macrophages, suggest ing no effect of even high doses on cyclooxygenase or PGI2 synthetase. This was confirmed by studies of aortic microsomes. The company also describes a study in which arachidonate infused into the ca rotid produced cerebral infarcts in 27 of 32 animals, presumably OR the basis of platelet aggregation (Furlow and Bass, 1976) . This incidence was re duced to 3 of 10 and 4 of 10 by pretreatment with 100 mg/kg of OKY and aspirin, respectively. In contrast to these data, we were unable to inhibit platelet aggregation in our model of aggregation, which may depend on endothelial damage produced by free radical generation from the interaction of light and fluorescein (Rosenblum and EI-Sabban, 19820) . Rather, aggregation was significantly en hanced, but only by a high dose of the drug. We have no explanation for the failure of lower doses or for the paradoxical effect of the high dose. It may be that, in our model, metabolic pathways other than those leading to thromboxane are so important for aggregation that blockade of thromboxane synthesis fails to impair aggregation. It may even be that blockade of thromboxane synthesis shunts arachi donate metabolism toward other proaggregatory pathways, for example, to PGE2. It is also pos sible that OKY -1581, especially at high doses, has properties not yet reported. Our inability to ex plain our result is reminiscent of the difficulty expe rienced by Crockard et al. (1982) in explaining how a thromboxane synthesis inhibitor diminished cere bral blood flow.
The injury of pial arterioles by the light/ fluorescein stimulus is consistently followed by di lation (Rosenblum et al., 1980; Rosenblum and EI Sabban, 19820) . In an initial study in which diame ters were monitored in 20 mice (Rosenblum and EI Sabban, 1977) , we failed to observe these changes, probably because of difficulties in visualizing the fluorescent vascular channel on the TV screen we were employing for monitoring diameter. Since then, we have used an ocular micrometer and have reported not only the dilation, but also the aug menting effects of cyclooxygenase inhibitors on that dilation (Rosenblum et al., 1980) . The cyc looxygenase inhibitors caused the dilations to in crease, presumably because the synthesis of con-stricting substances was reduced and a dilator, pos sibly a free radical generated by light/fluorescein (Rosenblum and El-Sabban, 19820) , was unop posed. Thromboxane, a potent constrictor of cere bral vessels (Ellis et aI., 1977) , is liberated from aggregating platelets (Smith, 1980) and would be one candidate for the constricting material(s) en gaged in a balance with the dilator(s). We would then expect the dilation following injury by light/ fluorescein to be enhanced by OKY-1581, an inhib itor of thromboxane synthesis, as was the case at the 300-mg/kg dose level in all three studies, two of which reached the level of statistical significance. If OKY-1581 is altering the response of diameter by inhibiting thromboxane synthesis, then this throws into even bolder relief the failure of OKY-1581 to impair platelet aggregation. As explained earlier, this failure may simply indicate that non-thrombox ane paths, which are well known to lead to aggre gation (Packham et aI., 1976) , play a very important role in this model.
In any case the present data do not support the hope that OK Y -1581 or similar drugs will be benefi cial in treating platelet aggregation in cerebral ves sels. A similar conclusion may have been drawn from our earlier failure to observe any effect of im idazole on platelet aggregation in this model (Rosenblum and El-Sabban, 1978) . The present data do, however, support a role for thromboxane syn thesis inhibitors in producing vasodilation or coun tering vasoconstriction. These statements are tem pered, of course, by the knowledge that drug effects may be dependent on the species studied, the mode of vascular injury employed, and the vascular bed or organ being examined. At present, the suggestion (e.g., Vermylen et aI., 1981) that thromboxane syn thesis inhibitors may be useful therapeutic agents certainly remains worthy of intensive testing.
